174 related articles for article (PubMed ID: 35667143)
41. In silico research on new sulfonamide derivatives as BRD4 inhibitors targeting acute myeloid leukemia using various computational techniques including 3D-QSAR, HQSAR, molecular docking, ADME/Tox, and molecular dynamics.
Belghalia E; Ouabane M; El Bahi S; Rehman HM; Sbai A; Lakhlifi T; Bouachrine M
J Biomol Struct Dyn; 2023 Sep; ():1-19. PubMed ID: 37656159
[TBL] [Abstract][Full Text] [Related]
42. New Research for Quinazoline-2,4-diones as HPPD Inhibitors Based on 2D-MLR and 3D-QSAR Models.
Fu Y; Sun YN; Cao HF; Yi KH; Zhao LX; Li JZ; Ye F
Comb Chem High Throughput Screen; 2017; 20(9):748-759. PubMed ID: 28637410
[TBL] [Abstract][Full Text] [Related]
43. PknB remains an essential and a conserved target for drug development in susceptible and MDR strains of M. Tuberculosis.
Gupta A; Pal SK; Pandey D; Fakir NA; Rathod S; Sinha D; SivaKumar S; Sinha P; Periera M; Balgam S; Sekar G; UmaDevi KR; Anupurba S; Nema V
Ann Clin Microbiol Antimicrob; 2017 Aug; 16(1):56. PubMed ID: 28821299
[TBL] [Abstract][Full Text] [Related]
44. In Silico Screen and Structural Analysis Identifies Bacterial Kinase Inhibitors which Act with β-Lactams To Inhibit Mycobacterial Growth.
Wlodarchak N; Teachout N; Beczkiewicz J; Procknow R; Schaenzer AJ; Satyshur K; Pavelka M; Zuercher W; Drewry D; Sauer JD; Striker R
Mol Pharm; 2018 Nov; 15(11):5410-5426. PubMed ID: 30285456
[TBL] [Abstract][Full Text] [Related]
45. Computational Investigations of Coumarin Derivatives as Cyclindependent Kinase 9 Inhibitors Using 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation.
Liu S; Li Y; Wei X; Zhang R; Zhang Y; Guo C
Curr Comput Aided Drug Des; 2022; 18(5):363-380. PubMed ID: 35980073
[TBL] [Abstract][Full Text] [Related]
46. Insight into the interaction mechanism of human SGLT2 with its inhibitors: 3D-QSAR studies, homology modeling, and molecular docking and molecular dynamics simulations.
Dong L; Feng R; Bi J; Shen S; Lu H; Zhang J
J Mol Model; 2018 Mar; 24(4):86. PubMed ID: 29511885
[TBL] [Abstract][Full Text] [Related]
47. 3D-QSAR and cell wall permeability of antitubercular nitroimidazoles against Mycobacterium tuberculosis.
Lee SH; Choi M; Kim P; Myung PK
Molecules; 2013 Nov; 18(11):13870-85. PubMed ID: 24217328
[TBL] [Abstract][Full Text] [Related]
48. Ursolic acid as a potential inhibitor of Mycobacterium tuberculosis cytochrome bc1 oxidase-a molecular modelling perspective.
Tembe N; Machaba KE; Ndagi U; Kumalo HM; Mhlongo NN
J Mol Model; 2022 Jan; 28(2):35. PubMed ID: 35022913
[TBL] [Abstract][Full Text] [Related]
49. CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors.
Kulkarni SS; Patel MR; Talele TT
Bioorg Med Chem; 2008 Apr; 16(7):3675-86. PubMed ID: 18299198
[TBL] [Abstract][Full Text] [Related]
50. Molecular modeling study of pyrrolidine derivatives as novel myeloid cell leukemia-1 inhibitors through combined 3D-QSAR, molecular docking, ADME/Tox and MD simulation techniques.
Tabti K; Baammi S; Sbai A; Maghat H; Lakhlifi T; Bouachrine M
J Biomol Struct Dyn; 2023; 41(23):13798-13814. PubMed ID: 36841617
[TBL] [Abstract][Full Text] [Related]
51. In silico design novel (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine derivatives as inhibitors for glycogen synthase kinase 3 based on 3D-QSAR, molecular docking and molecular dynamics simulation.
He Q; Han C; Li G; Guo H; Wang Y; Hu Y; Lin Z; Wang Y
Comput Biol Chem; 2020 Oct; 88():107328. PubMed ID: 32688011
[TBL] [Abstract][Full Text] [Related]
52. Molecular docking, molecular dynamics simulations and binding free energy studies of interactions between Mycobacterium tuberculosis Pks13, PknG and bioactive constituents of extremophilic bacteria.
Nyambo K; Tapfuma KI; Adu-Amankwaah F; Julius L; Baatjies L; Niang IS; Smith L; Govender KK; Ngxande M; Watson DJ; Wiesner L; Mavumengwana V
Sci Rep; 2024 Mar; 14(1):6794. PubMed ID: 38514663
[TBL] [Abstract][Full Text] [Related]
53. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
54. Integrated molecular docking, 3D QSAR and molecular dynamics simulation studies on indole derivatives for designing new Pim-1 inhibitors.
Peddi SR; Peddi SR; Sivan S; Veerati R; Manga V
J Recept Signal Transduct Res; 2020 Feb; 40(1):1-14. PubMed ID: 31931654
[TBL] [Abstract][Full Text] [Related]
55. 3D-QSAR-aided design of potent c-Met inhibitors using molecular dynamics simulation and binding free energy calculation.
Balasubramanian PK; Balupuri A; Bhujbal SP; Cho SJ
J Biomol Struct Dyn; 2019 May; 37(8):2165-2178. PubMed ID: 30044205
[TBL] [Abstract][Full Text] [Related]
56. A Comparative Study of 1D Descriptors Supported CoMFA and CoMSIA QSAR Models to Gain Novel Insights into 1,2,4-Triazoles Acting As Antitubercular Agents.
Ray R; Shenoy GG; Kumar TNVG
Curr Comput Aided Drug Des; 2021; 17(2):281-293. PubMed ID: 32116196
[TBL] [Abstract][Full Text] [Related]
57. Binding Studies and Lead Generation of Pteridin-7(8
Ghosh S; Cho SJ
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887060
[TBL] [Abstract][Full Text] [Related]
58. Identification of potent L,D-transpeptidase 5 inhibitors for Mycobacterium tuberculosis as potential anti-TB leads: virtual screening and molecular dynamics simulations.
Sabe VT; Tolufashe GF; Ibeji CU; Maseko SB; Govender T; Maguire GEM; Lamichhane G; Honarparvar B; Kruger HG
J Mol Model; 2019 Oct; 25(11):328. PubMed ID: 31656981
[TBL] [Abstract][Full Text] [Related]
59. 3D-QSAR, molecular docking, and molecular dynamics analysis of dihydrodiazaindolone derivatives as PARP-1 inhibitors.
Zhao J; Yu N; Zhao X; Quan W; Shu M
J Mol Model; 2023 Apr; 29(5):131. PubMed ID: 37020092
[TBL] [Abstract][Full Text] [Related]
60. QSAR Modeling, Molecular Docking and Molecular Dynamics Simulations Studies of Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Anticancer Agents.
Abdizadeh R; Heidarian E; Hadizadeh F; Abdizadeh T
Anticancer Agents Med Chem; 2021; 21(8):987-1018. PubMed ID: 32698753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
